Navigation Links
miniTHERM T (230V / 50Hz)

ProductsminiTHERM T (230V / 50Hz)
Company Sartorius AG
Item miniTHERM T (230V / 50Hz)
Features 
Description A wide range of miniTHERM incubators is available, ensuring the customers to find the appropriate application solution for their specific requirements. miniTHERM incubators have a capacity of 18 liters, are compact and extremely space saving. Their size corresponds approximately to a typical microwave oven. It is possible to stack up to three units on top of each other. The units have a one-piece plastic casing. The inside corners have been rounded to make cleaning easy. This glass-like surface coating makes the interior easy to clean. The incubators are equipped with a digital temperature control unit and optional CO2 gassing.
miniTHERM T, the standard model, is fitted with a digital temperature control unit with a maximum temperature of 50 C. Up to 4 shelves can be fitted inside. The maximum available surface area can therefore be extended to 4 x 1100 cm2.
Info Sartorius AG
Customer Service: +49.551.308.0
Web site: http://www.sartorius.com/

Related medicine products :

1. miniTHERM CTT (230V / 50Hz)
2. miniTHERM T (120V / 60Hz)
3. miniTHERM CTT (120V / 60Hz)
4. Accucount 1000 (230V/50Hz)
5. Accucount 2000 (230V/50Hz)
6. miniPERM CT (230V / 50Hz)
7. Salter AIRE Plus® Portable Treatment Compressor (230V) European Model
8. Salter AIRE Plus® Portable Treatment Compressor (230V) United Kingdom Model
9. CA-1000 (220V/50Hz)
10. BE-1200 (220V/50Hz)
TAG: miniTHERM
For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution.
For the quantitative determination of total glucose in serum.
Glucose reagent is used for the quantitative determination of glucose in human serum.
Intended for the quantitative determination of glucose in biological fluids. Reaction: endpoint. Wavelength: 340 nm. Linearity: 800 mg/dL (44.4 mmol/L). Single vial, dry powder reagent.
Medicine Products:
(Date:11/21/2008)...y lead to new therapies for preterm labor , ...ers say they,ve found the switch that activates th...h, a finding that may lead to therapies for preter...binds the protein IP on the surface of these uteri...during pregnancy. , But researchers from Dartm...
(Date:11/21/2008)...eting of shareholders to be held on January 8, 200...l/ - Med-Emerg International Inc. ("MedEmerg") (OT...ealth services, announced today that it has obtain...t of Justice concerning its previously announced p... which AIM Health Group Inc. ("AIM") will acquire ...
(Date:11/21/2008)...ov. 21, 2008)The University of Texas Health Scienc...ining Excellence in Aging Studies (TEXAS), to prom...restigious $2 million award from the Donald W. Rey...ds., "This will allow us to teach geriatric medic...dical student to practicing physicians. With the r...
(Date:11/21/2008)...Colo., Nov. 21 Heska Cor...l present at the New York Society of,Security Ana...nference on,December 2, 2008 at 1177 Avenue of th...tation is scheduled to begin at 9:35 a.m. Eastern ...ble via live webcast and for two weeks,following ...
Breaking Medicine News(10 mins):Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 2Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4
...Crawford, the former commissioner of the Food and ...l investigation following accusations of financial...s mentioned that a grand jury had begun a criminal... is believed to have told a federal magistrate, in...
... Spinal Meningitis (CSM) has claimed five lives af...oto State. // A parallel outbreak of measles has a...of lives. The five dead persons were among the fou...be suffering from the CSM infections. The state m...
...earchers at Emory University School of Medicine in...tted images are very efficient in the evaluation o...d and its accuracy of diagnosis is incomparable. ...the MDCTs of 50 patients referred for GI tract ima...
...so have become victims to disorders like anorexia ... But a UK study showed that 500 teenagers are affe...iends. The research is published in the British Jo... analyze the gap in the literature and look at wha...
Other Medicine News:
(Date:11/18/2008)...RNewswire-USNewswire/ -- Forty-two leading U. S. s...ational forum to consider cutting-edge innovations...nal economy from outbreaks of dangerous zoonotic d... Among those innovations: , , , , ...ble that detects highly contagious and dangerous z...
(Date:11/13/2008)...3 Hologic, Inc.,(Nasdaq:...pplier of premium,diagnostics, medical imaging sys...e healthcare needs of women, today announced the r...cal trial. The Cervista HPV high-risk,test is curr...xpected to be,launched in the European Union (EU) ...
(Date:11/12/2008)...ewswire-USNewswire/ -- A new study being,published... answer the,question, what causes Parkinson,s dise...edical research into,Parkinson,s disease is what c...he first place. Answering this question has been e...dentical types of brain cells that produce,dopamin...
(Date:11/12/2008)...0128 Provides Reversible, High-level Platelet ... -, NEW ORLEANS and SOUTH SAN FRANCISCO, Calif., ... biopharmaceutical company developing innovative,d...scular and inflammatory,diseases, and cancer, toda...060128, the Company,s novel anti-platelet drug tha...
Breaking Medicine Technology:42 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 3Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 4A Window Into Parkinson's Disease 2Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders 2Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders 3Health and Business Groups Launch Ad Campaign About Need for Comprehensive Smoke Free Law in Pennsylvania 992 1Health and Business Groups Launch Ad Campaign About Need for Comprehensive Smoke Free Law in Pennsylvania 992 2Health and Business Groups Launch Ad Campaign About Need for Comprehensive Smoke Free Law in Pennsylvania 992 3Slowed Brain Activity in Frequent Mobile Phone Users 989 1Slowed Brain Activity in Frequent Mobile Phone Users 989 2LOreal Paris Celebrates Ten Years of Hope and Healing 986 1LOreal Paris Celebrates Ten Years of Hope and Healing 986 2LOreal Paris Celebrates Ten Years of Hope and Healing 986 3LOreal Paris Celebrates Ten Years of Hope and Healing 986 4LOreal Paris Celebrates Ten Years of Hope and Healing 986 5The Pittsburgh Life Sciences Greenhouse Adds to Its Investment Portfolio 501 1The Pittsburgh Life Sciences Greenhouse Adds to Its Investment Portfolio 501 2The Pittsburgh Life Sciences Greenhouse Adds to Its Investment Portfolio 501 3The Pittsburgh Life Sciences Greenhouse Adds to Its Investment Portfolio 501 4
... 25, 2007 - ARIAD,Pharmaceuticals, Inc. (NASDAQ: A...rom leading cancer centers will present Phase 2 an...any,s novel mTOR,inhibitor, AP23573, at the annual...ogy (ASCO) in Chicago, Illinois, on Sunday, June,3...single-agent,AP23573 in patients with soft-tissue ...
...wswire-FirstCall/ -- Iomai,Corporation today annou...1 trial of its patch-based needle-free influenza v...nce call and live,webcast will be held at 8:30 a.m...Conference Call Details , To access the live confe...rn Time via phone, please dial 888-396-2356 from t...
Other Medicine Technology:Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 2Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 3Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 4Iomai to Announce Results From Phase 1 Influenza Trial and Host,Webcast Tomorrow 2